Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
PaperCitations, authors & open-access status
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 233 citations, 2022 year and closed oa status.
233
Citations
2022
Year
closed
OA Status